K. Schlichtig

The Randomized AMBORA Trial: Impact of Pharmacological/Pharmaceutical Care on Medication Safety and Patient-Reported Outcomes During Treatment With New Oral Anticancer Agents

M. Beckmann, M. Neurath, M. Fromm, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An Easily Expandable Multi-Drug LC-MS Assay for the Simultaneous Quantification of 57 Oral Antitumor Drugs in Human Plasma

M. Fromm, A. Mackensen, B. Wullich, 2021, Cancers.

New Oral Anti-Cancer Drugs and Medication Safety.

M. Fromm, F. Dörje, P. Dürr, 2019, Deutsches Arzteblatt international.

New Oral Antitumor Drugs and Medication Safety in Uro-Oncology: Implications for Clinical Practice Based on a Subgroup Analysis of the AMBORA Trial

M. Fromm, A. Mackensen, B. Wullich, 2022, Journal of clinical medicine.

Characteristics and Cost of Unscheduled Hospitalizations in Patients Treated with New Oral Anticancer Drugs in Germany: Evidence from the Randomized AMBORA Trial

M. Fromm, F. Meier, F. Dörje, 2022, Journal of clinical medicine.

Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study

M. Fromm, F. Dörje, P. Dürr, 2021, Clinical pharmacology and therapeutics.

Optimizing Medication Safety with Oral Antitumor Therapy: A Methodological Approach for the Real-World Implementation of the AMBORA Competence and Consultation Center

E. Inwald, M. Fromm, F. Dörje, 2023, Healthcare.

From the Randomized AMBORA Trial to Clinical Practice: Comparison of Medication Errors in Oral Antitumor Therapy

P. Dürr, K. Schlichtig, Lisa Cuba, 2024, Clinical pharmacology and therapeutics.